Jeff Yass’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-62,800
| Closed | -$2.37M | – | 13719 |
|
|
2021
Q1 | $2.37M | Buy |
62,800
+35,800
| +133% | +$893K | ﹤0.01% | 5512 |
|
|
2020
Q4 | $459K | Buy |
27,000
+13,800
| +105% | +$173K | ﹤0.01% | 8480 |
|
|
2020
Q3 | $62K | Buy |
+13,200
| New | +$67K | ﹤0.01% | 10143 |
|
|
2020
Q2 | – | Sell |
-10,800
| Closed | -$25K | – | 11342 |
|
|
2020
Q1 | $25K | Buy |
+10,800
| New | +$45.8K | ﹤0.01% | 9891 |
|
|
2019
Q2 | – | Sell |
-26,000
| Closed | -$348K | – | 11113 |
|
|
2019
Q1 | $348K | Buy |
26,000
+14,300
| +122% | +$163K | ﹤0.01% | 6959 |
|
|
2018
Q4 | $109K | Sell |
11,700
-75,100
| -87% | -$894K | ﹤0.01% | 8176 |
|
|
2018
Q3 | $1.21M | Buy |
86,800
+55,800
| +180% | +$830K | ﹤0.01% | 4864 |
|
|
2018
Q2 | $490K | Buy |
+31,000
| New | +$541K | ﹤0.01% | 6828 |
|
|
2018
Q1 | – | Sell |
-37,500
| Closed | -$822K | – | 10548 |
|
|
2017
Q4 | $822K | Sell |
37,500
-28,500
| -43% | -$917K | ﹤0.01% | 5632 |
|
|
2017
Q3 | $2.7M | Buy |
66,000
+53,900
| +445% | +$1.69M | ﹤0.01% | 3391 |
|
|
2017
Q2 | $364K | Sell |
12,100
-10,900
| -47% | -$340K | ﹤0.01% | 7227 |
|
|
2017
Q1 | $831K | Buy |
23,000
+7,500
| +48% | +$331K | ﹤0.01% | 5526 |
|
|
2016
Q4 | $777K | Buy |
15,500
+8,300
| +115% | +$436K | ﹤0.01% | 6051 |
|
|
2016
Q3 | $378K | Sell |
7,200
-2,500
| -26% | -$119K | ﹤0.01% | 6557 |
|
|
2016
Q2 | $401K | Sell |
9,700
-3,400
| -26% | -$148K | ﹤0.01% | 6491 |
|
|
2016
Q1 | $532K | Sell |
13,100
-23,200
| -64% | -$797K | ﹤0.01% | 6292 |
|
|
2015
Q4 | $1.51M | Buy |
+36,300
| New | +$1.22M | ﹤0.01% | 4613 |
|
Jeff Yass's FPRX Position: Q2 2021 in Review
Jeff Yass sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 29,986 shares — an estimated $1.13M sold.
Jeff Yass first reported a position in FPRX in Q1 2015 and held it in 10 quarters. The position peaked at $1.13M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Jeff Yass reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Jeff Yass sold 29,986 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.13M.
- Jeff Yass first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
- Jeff Yass's Five Prime Therapeutics, Inc. position peaked at $1.13M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Susquehanna International Group's 13F filing for Q2 2021, filed 11 Aug 2021.